# Maria Dall’Era

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/maria-dall-era/

## Facts

| Field | Value |
| --- | --- |
| Citations | 6,085 |
| Field | Systemic Lupus Erythematosus Research |
| h-index | 41 |
| i10-index | 87 |
| OpenAlex ID | https://openalex.org/A5034127273 |
| ORCID iD | 0000-0001-7439-2316 |
| Works | 215 |

## Researcher papers

- [Single-cell RNA-seq reveals cell type–specific molecular and genetic associations to lupus](https://scholariq.org/papers/single-cell-rna-seq-reveals-cell-type-specific-molecular-and-genetic/)
- [Predictors of Long‐Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro‐Lupus Nephritis Cohort](https://scholariq.org/papers/predictors-of-long-term-renal-outcome-in-lupus-nephritis-trials-lessons-learned/)
- [Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating trial](https://scholariq.org/papers/reduced-b-lymphocyte-and-immunoglobulin-levels-after-atacicept-treatment-in/)
- [Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta‐Analysis of the Centers for Disease Control and Prevention National Lupus Registries](https://scholariq.org/papers/prevalence-of-systemic-lupus-erythematosus-in-the-united-states-estimates-from-a/)
- [Type I interferon correlates with serological and clinical manifestations of SLE](https://scholariq.org/papers/type-i-interferon-correlates-with-serological-and-clinical-manifestations-of-sle/)
- [A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the <i>MAINTAIN Nephritis Trial</i>](https://scholariq.org/papers/a-proteinuria-cut-off-level-of-0-7-g-day-after-12-months-of-treatment-best/)
- [Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis](https://scholariq.org/papers/phase-ii-randomized-trial-of-rituximab-plus-cyclophosphamide-followed-by/)
- [Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis](https://scholariq.org/papers/peripheral-blood-b-cell-depletion-after-rituximab-and-complete-response-in-lupus/)
- [The Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, California: The California Lupus Surveillance Project](https://scholariq.org/papers/the-incidence-and-prevalence-of-systemic-lupus-erythematosus-in-san-francisco/)
- [Adoptive Treg Cell Therapy in a Patient With Systemic Lupus Erythematosus](https://scholariq.org/papers/adoptive-treg-cell-therapy-in-a-patient-with-systemic-lupus-erythematosus/)
- [Real-world treatment utilization and economic implications of lupus nephritis disease activity in the United States](https://scholariq.org/papers/real-world-treatment-utilization-and-economic-implications-of-lupus-nephritis/)

## Researcher topics

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [T-cell and B-cell Immunology](https://scholariq.org/topics/t-cell-and-b-cell-immunology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.